Researchers from the University of Queensland and affiliated organizations recently presented preclinical data for the novel C3a receptor (C3aR) antagonist JR-14a, being developed as a neuroprotective agent for the treatment of post-stroke neuroinflammation.
The rare hereditary fibrinogen disorder hypodysfibrinogenemia is characterized by fibrinogen defects, which can cause thrombotic and hemorrhagic phenotypes that are not always predicted by routine coagulation tests. Researchers from Academic Hospital Maastricht aimed to characterize the genetic profile of a family with hypodysfibrinogenemia and predict bleeding and/or thrombotic phenotypes in asymptomatic family members using innovative testing.
Biopsies from up to 14% of patients with non-small-cell lung cancer (NSCLC) showing resistance to epidermal growth factor receptor (EGFR) tyrosine kinase therapy ascertain histologic transformation (HT) to SCLC, which is estimated to kill around 250,000 patients globally, every year. In a study published in Science on Feb. 9, 2024, researchers from Weill Cornell Medicine have dissected that complex process using a genetically engineered mouse model of pulmonary HT.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented phosphorylpurinone compounds acting as Toll-like receptor 7 (TLR7) agonists reported to be useful for the treatment of cancer.
Incyte Corp. has developed fused tricyclic compounds acting as GTPase KRAS (mutant) inhibitors. As such, they are reported to be useful for the treatment of cancer, inflammation and immunological disorders.
Work at Jnana Therapeutics Inc. has led to the identification of sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of diabetes, chronic kidney disease, metabolic dysfunction-associated steatohepatitis (MASH), phenylketonuria, metabolic syndrome, obesity, neurodevelopmental and autism spectrum disorders, among others.
Protein arginine N-methyltransferase 5 (PRMT5) inhibitors have been disclosed in an Abbisko Therapeutics Co. Ltd. patent and described as potentially useful for the treatment of cancer.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described new 5’-nucleotidase (CD73) inhibitors reported to be useful for the treatment of cancer.
Researchers from National Taiwan University combined the structural features of purine-type microtubule-disrupting compounds and histone deacetylase (HDAC) inhibitors, which led to the discovery of a novel series of dual-targeting compounds, with the purine-hydroxamate conjugate [I] selected as the lead candidate.
RSS
